AI assistant
Sending…
PALISADE BIO, INC. — Director's Dealing 2022
Feb 10, 2022
35274_dirs_2022-02-10_caf2f1f2-4dd2-4003-b035-429c3a3b35eb.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: PALISADE BIO, INC. (PALI)
CIK: 0001357459
Period of Report: 2021-11-18
Reporting Person: Dawson Michael John (Chief Medical Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-11-18 | Stock Option (right to buy) | $2.32 | A | 39294 | Acquired | 2031-11-17 | Common Stock (39294) | Direct |
Footnotes
F1: 1/12th of the shares underlying the Stock Option shall vest and become exercisable on each three-month anniversary of the vesting commencement date and if there is no corresponding day, the last day of the month.
More from PALISADE BIO, INC.
Capital/Financing Update
2026
May 12
Interim / Quarterly Report
2026
May 12
Annual Report
2026
Apr 29
Capital/Financing Update
2026
Apr 2
Annual Report
2026
Mar 20
Major Shareholding Notification
2026
Feb 17
Director's Dealing
2026
Feb 13
Major Shareholding Notification
2026
Feb 13
Director's Dealing
2026
Feb 13
Director's Dealing
2026
Feb 11